Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 696 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QMUH | ISIN: US92790C1045 | Ticker-Symbol: 1S1
Tradegate
31.03.25
10:10 Uhr
13,600 Euro
+0,200
+1,49 %
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
VIRIDIAN THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
VIRIDIAN THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
13,00013,60010:55
13,00013,60010:37

Aktuelle News zur VIRIDIAN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.03.Viridian Therapeutics Announces Inducement Stock Option Grants1
10.03.Viridian Therapeutics, Inc.\DE - 8-K, Current Report1
03.03.Viridian Therapeutics, Inc.\DE - S-8, Securities to be offered to employees in employee benefit plans-
03.03.Viridian Therapeutics, Inc.\DE - 10-K, Annual Report-
27.02.Viridian Therapeutics GAAP EPS of -$0.81 beats by $0.24, revenue of $0.07M beats by $0.02M2
27.02.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
13.02.Viridian Therapeutics (NASDAQ:VRDN) Trading Down 5% - Here's Why2
VIRIDIAN THERAPEUTICS Aktie jetzt für 0€ handeln
10.01.Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
07.01.Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts1
19.12.24Viridian Therapeutics (NASDAQ:VRDN) Shares Gap Down - Time to Sell?3
17.12.24Breaking Down Viridian Therapeutics: 10 Analysts Share Their Views1
17.12.24Viridian Therapeutics (NASDAQ:VRDN) Price Target Raised to $47.00 at Royal Bank of Canada4
17.12.24Lord Abbett & CO. LLC Purchases New Stake in Viridian Therapeutics, Inc. (NASDAQ:VRDN)1
16.12.24Viridian Therapeutics' (VRDN) "Buy" Rating Reaffirmed at HC Wainwright3
16.12.24Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease39
16.12.24Viridian Therapeutics, Inc.\DE - 8-K, Current Report-
12.11.24Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data191WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare...
► Artikel lesen
28.10.24Needham maintains buy on VRDN shares, cites recent clinical trial results4
28.10.24Analyst Expectations For Viridian Therapeutics' Future5
23.10.24Viridian Therapeutics (VRDN): A Small-Cap Biotech with Promising Clinical Results3
Seite:  Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1